Tandem Diabetes Care | TNDM - Operating Expenses


Tandem Diabetes Care reported $282.09M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Accuray USD 37.18M 567K Dec/2024
Align Technology USD 822.85M 11.8M Dec/2025
AtriCure USD 138.01M 3.95M Dec/2025
Baxter International USD 3.19B 554.4M Dec/2025
Becton, Dickinson and Co. USD 4.59B 476M Dec/2025
Boston Scientific USD 4.04B 18M Dec/2025
Cooper Companies USD 924.8M 40.2M Sep/2025
Dexcom USD 936.6M 30.2M Dec/2025
Edwards Lifesciences USD 1.2B 71.3M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Globus Medical USD 886.57M 730.06M Sep/2025
ICU Medical USD 514.62M 4.48M Dec/2025
Inogen USD 49.14M 665K Sep/2024
Insulet USD 637.5M 48.9M Dec/2025
Integra LifeSciences USD 1.04B 620.66M Sep/2025
Intuitive Surgical USD 2B 263.6M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Masimo USD 147M 159.4M Sep/2025
Medtronic USD 7.28B 16M Dec/2025
Merit Medical Systems USD 341.54M 6.11M Sep/2025
Orthofix International USD 10.89M 209.57M Sep/2024
Roche Holding CHF 21.01B 10.84B Dec/2025
Stryker USD 5.2B 505M Dec/2025
Tandem Diabetes Care USD 282.09M 9.97M Dec/2025
Teleflex USD 3.82B 3.22B Sep/2025
Zimmer Biomet Holdings USD 1.94B 277.8M Dec/2025